Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders

Paton, DM

Paton, DM (corresponding author), 2416 Brandon Way, Nanaimo, BC V9T 0G2, Canada.

DRUGS OF TODAY, 2021; 57 (3): 209

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic ner......

Full Text Link